CD274 and ductal breast carcinoma in situ: To further improve the efficacy of the combined HS201-PDT and anti-PD-L1 treatment for the prevention of DCIS progression, we repeated HS201-PDT once a week for 4 weeks while administering anti-PD-L1 weekly (Figure 5D).